基本信息
浏览量:1
职业迁徙
个人简介
Dr Wilmott is a current NHMRC research fellow, 2020 NHMRC investigator fellow, senior lecturer at The University of Sydney and research leader of the Melanoma Translational Pathology Research Group (MTPRG) at the Charles Perkins Center, The University of Sydney. Dr Wilmott leads the large 25+ research team whose research interests spans areas such as primary melanoma diagnosis, melanoma biology, systemic therapies in advanced disease and more recently the development of personalized immunotherapies for metastatic melanoma.
Dr Wilmott is internationally recognized as an emerging expert in clinical implications of genomic profiles (First author Nature and Int J Cancer), immune profiling of cancer tissue (Co-author in Nature, The Lancet Oncology, senior author in Clinical Cancer Research and Oncoimmunology) and in biomarker discovery of systemic therapies (Senior author Cancer Cell). Dr Wilmott co-leads multople international programs of research that have made significant contributions to the knowledge in the melanoma genomics. This includes research that has described in unprecedented detail the somatic mutations that occur in a large cohort of cutaneous melanomas and melanomas that have arisen in mucosal (female genital and anorectal tract), acral (hands and feet) and the critical unmet need of childhood melanoma. This work has generated new knowledge with multiple publications (including in Nature, Laboratory Investigation, Oncotarget, J Invest Derm, Int J Cancer and Pathology). I am a significant contributor to this body of work as reflected by the first or senior authorship on 6/7 publications and contributed funding as CIA on grants focusing on childhood melanoma.
A major focus of Dr Wilmott’s research is the integrate clinical, multi-omic and pathological data into the selection of systemic therapies for metastatic melanoma patients. Dr Wilmott is a world leader in highly multiplexed immune profiling in melanoma patients’ tissue and the correlates with transcriptomics and clinical response to immunotherapies (Cancer Cell 2019). Dr Wilmott has experience in immunotherapy drug discovery in melanoma biopsies (Clin Cancer Res 2019) and his work applies the above skills and expertise to uncover effective treatment options for the more that 50% of melanoma patients not responding to current therapies.
研究兴趣
论文共 299 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 6_Supplement (2024): 5563-5563
SCIENCE IMMUNOLOGYno. 91 (2024): eadi9517-eadi9517
Cancer Researchno. 6_Supplement (2024): 7531-7531
Georgina Long,James Wilmott,Elena Shklovskaya, Laveniya Satgunseelan,Yizhe Mao, Kristen Perry,Russell Diefenbach,Tuba Gide,Brindha Shivalingam,Michael Buckland,Maria Gonzalez, Nicole Caixeiro,
crossref(2024)
Cancer Researchno. 6_Supplement (2024): 6681-6681
Cancer Researchno. 7_Supplement (2023): 3463-3463
J. Paluncic,M. Gholam Azad,D.J.R Lane,J. Skoda, K.C. Park, S. Chiang,D.H. Bae,R. Scolyer,R. Afroz, G. Babu,J. Wilmott,K. Loh,
biorxiv(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn